Sangamo Therapeutics Inc (SGMO)
0.5143
+0.03
(+5.98%)
USD |
NASDAQ |
Apr 19, 16:00
0.5143
0.00 (0.00%)
After-Hours: 20:00
Sangamo Therapeutics Enterprise Value: 5.821M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 5.821M |
| April 17, 2024 | 11.31M |
| April 16, 2024 | 15.97M |
| April 15, 2024 | 18.31M |
| April 12, 2024 | 16.22M |
| April 11, 2024 | 16.54M |
| April 10, 2024 | 12.74M |
| April 09, 2024 | 19.62M |
| April 08, 2024 | 20.15M |
| April 05, 2024 | 19.40M |
| April 04, 2024 | 21.82M |
| April 03, 2024 | 28.13M |
| April 02, 2024 | 23.01M |
| April 01, 2024 | 27.70M |
| March 28, 2024 | 38.90M |
| March 27, 2024 | 30.76M |
| March 26, 2024 | 26.95M |
| March 25, 2024 | 33.80M |
| March 22, 2024 | 44.77M |
| March 21, 2024 | 92.59M |
| March 20, 2024 | 65.00M |
| March 19, 2024 | 56.76M |
| March 18, 2024 | 71.25M |
| March 15, 2024 | 58.54M |
| March 14, 2024 | 58.54M |
| Date | Value |
|---|---|
| March 13, 2024 | 59.46M |
| March 12, 2024 | 73.05M |
| March 11, 2024 | 76.86M |
| March 08, 2024 | 81.11M |
| March 07, 2024 | 82.76M |
| March 06, 2024 | 98.91M |
| March 05, 2024 | 102.48M |
| March 04, 2024 | 100.69M |
| March 01, 2024 | 116.73M |
| February 29, 2024 | 125.63M |
| February 28, 2024 | 109.60M |
| February 27, 2024 | 120.29M |
| February 26, 2024 | 118.51M |
| February 23, 2024 | 120.29M |
| February 22, 2024 | 114.94M |
| February 21, 2024 | 138.99M |
| February 20, 2024 | 129.20M |
| February 16, 2024 | 164.82M |
| February 15, 2024 | 106.04M |
| February 14, 2024 | 53.28M |
| February 13, 2024 | 38.37M |
| February 12, 2024 | 62.40M |
| February 09, 2024 | 21.32M |
| February 08, 2024 | 16.97M |
| February 07, 2024 | 5.339M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-79.42M
Minimum
Nov 10 2023
1.922B
Maximum
Dec 23 2020
571.60M
Average
592.64M
Median
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 11.42M |
| Perspective Therapeutics Inc | 855.25M |
| Protalix BioTherapeutics Inc | 58.24M |
| Electromed Inc | 109.52M |
| Armata Pharmaceuticals Inc | 160.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.30M |
| Revenue (Quarterly) | 2.042M |
| Total Expenses (Quarterly) | 63.80M |
| EPS Diluted (Quarterly) | -0.34 |
| Profit Margin (Quarterly) | -2.95K% |
| Earnings Yield | -285.8% |
| Normalized Earnings Yield | -125.66 |